Major depressive disorder (MDD) is a common illness accompanied by considerable
morbidity, mortality, costs, and heightened risk of suicide. We conducted a genome-wide …

Background: This report provides histopathological evidence to support prior neuroimaging
findings of decreased volume and altered metabolism in the frontal cortex in major …

BACKGROUND: Imaging studies report that hippocampal volume is decreased in major
depressive disorder (MDD). A cellular basis for reduced hippocampal volume in MDD has not …

Previous imaging and postmortem studies have reported a lower brain volume and a smaller
size and density of neurons in the dorsolateral prefrontal cortex (dlPFC) of subjects with …

It has been hypothesized that a deficit in serotonin may be a crucial determinant in the
pathophysiology of major depression. Serotonin-1A receptors are located on serotonin cell bodies …

The norepinephrine transporter (NET) is a membrane protein responsible for termination of
the action of synaptic norepinephrine and is a site of action of many drugs used to treat major …

Post-mortem morphometric studies report reductions in the average density and size of
cortical neurons in the dorsolateral prefrontal cortex (dlPFC) and orbitofrontal cortex (ORB) in …

Chronic administration of nicotine increases the density of neuronal cholinergic nicotinic
receptors in cells and in rodent brain, and similar increases have been reported in brains from …

Recent neuroimaging and postmortem studies have demonstrated abnormalities in glutamatergic
transmission in major depression. Glutamate NMDA (N-methyl-d-aspartate) receptors …

The lifetime prevalence (∼16%) 1 and the economic burden ($100 billion annually) 2 , 3
associated with major depressive disorder (MDD) make it one of the most common and …